The entry of pegylated liposomes from blood vessels and their acc

The entry of pegylated liposomes from blood vessels and their accumulation in tumours have been tested in mice bearing C-26 colon carcinoma tumours and in transgenic mice with KS-like lesions. The pegylated liposomes also combine a low permeability lipid matrix with an internal aqueous buffer system that keeps doxorubicin hydrochloride encapsulated as long as liposomes remain in the blood stream. Myocet (liposome-encapsulated doxorubicin Inhibitors,research,lifescience,medical citrate) is another form of encapsulated doxorubicin hydrochloride consisting of a drug delivery system with a highly rigid Dorsomorphin mechanism bilayer [20]. Myocet (LD) also provides a more prolonged circulating time than conventional doxorubicin

and, in addition, liposome-encapsulation significantly modifies the biodistribution of doxorubicin, resulting in reduced toxicity. The clearance of LD was 5.1 ± 4.8L/h and steady-state volume of Inhibitors,research,lifescience,medical distribution (Vd) was 56.6 ± 61.5L whereas, after conventional doxorubicin elimination and (Vd) were 46.7 ± 9.6L/h and 1.451 ± 258L, respectively [21]. In animals (Table 1), liposome-encapsulated doxorubicin reduced the distribution to the heart

and the gastrointestinal mucosa compared to conventional doxorubicin, while http://www.selleckchem.com/products/Abiraterone.html antitumor efficacy was maintained. However, when compared with conventional doxorubicin, LD did not prove to be more active in Inhibitors,research,lifescience,medical doxorubicin-resistant cell lines. Table 1 Comparison of AUC and t1/2 in various tissues in dogs following the administration of TLC D-99 and conventional doxorubicin. Single dose 1.5mg/kg (30mg·m−2), IV [18]. Doxorubicin plasma pharmacokinetics in patients receiving LD showed a high degree of interpatient variability. Nonetheless, as a rule, total doxorubicin plasma levels were significantly higher with Inhibitors,research,lifescience,medical LD than with conventional doxorubicin, while free doxorubicin peak plasma levels were lower.

Similarly, the peak levels of the main circulating doxorubicin metabolite, doxorubicinol (synthesized Inhibitors,research,lifescience,medical via aldo-keto-reductase) appeared in plasma later with LD than with conventional doxorubicin. Available pharmacokinetic data preclude settling strong conclusions regarding the relationship between plasma levels of total/free doxorubicin and its influence on the efficacy/safety of LD. 3. Anthracycline Toxicity Anthracyclines have a well-known toxicity profile. Their more frequent side effects include myelosuppression, mucositis, alopecia, and emesis. Other AV-951 less frequent although highly relevant side effects are cardiotoxicity and the occurrence of secondary leukemias. The emetogenic potential of anthracyclines is moderate even though it is potentiated by other agents when administered in combination. The lowest blood cell count (nadir) is reached between 10 and 14 days after administration. Doxorubicin is a potent vesicant agent and its extravasation may cause necrosis of the skin and soft tissue.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>